Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID... see more

Recent & Breaking News (NDAQ:NVAX)

Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering

GlobeNewswire June 11, 2014

Novavax Prices Public Offering of Common Stock

GlobeNewswire June 5, 2014

Novavax Announces Proposed Public Offering of Common Stock

GlobeNewswire June 4, 2014

Novavax to Present at the Jefferies 2014 Global Healthcare Conference

GlobeNewswire June 2, 2014

One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response

GlobeNewswire May 12, 2014

Novavax Reports First-Quarter 2014 Financial Results

GlobeNewswire May 7, 2014

Novavax Appoints Sven Andreasson as Senior Vice President, Corporate Development

GlobeNewswire May 6, 2014

Novavax to Report First Quarter Financial Results on May 7, 2014

GlobeNewswire May 1, 2014

New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

GlobeNewswire April 30, 2014

Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age

GlobeNewswire April 28, 2014

Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May

Accesswire April 11, 2014

Novavax Appoints Dr. Cindy Oliver as Senior Vice President, Process Development Operations

GlobeNewswire April 7, 2014

Novavax to Present at the 13th Annual Needham Healthcare Conference

Thomson Reuters ONE April 2, 2014

Novavax to Present at the 13th Annual Needham Healthcare Conference

GlobeNewswire April 2, 2014

Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies

Business Wire April 1, 2014

Microvision Raises $13.9 Million with New Stock Offering

Accesswire March 27, 2014

Global Headwinds Send Wall Street Lower for Second Session

Equities.com March 24, 2014

Novavax (NVAX) Plunges on Insider Sale, Continues Downtrend in Devastating Month of March

Equities.com March 24, 2014

Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)

GlobeNewswire March 10, 2014

Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations

Thomson Reuters ONE March 10, 2014